VERV Verve Therapeutics Inc
1,592
$5.24
0.76%
| Watchers | 1,592 |
| 52-Wk Low | $5.23 |
| 52-Wk High | $21.42 |
| Market Cap | $414.74M |
| Volume | 1.27M |
| 52-Wk High | $21.42 |
| 52-Wk Low | $5.23 |
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities lawsPR Newswire • about 1 month ago
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws Wolf Haldenstein Adler Freeman & Herz LLP...
Share to Feed
Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 1,514 shares of Verve Therapeutics stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause...
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT...
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verve Therapeutics, Inc...
For the last three days, A.I.dvisor has detected that VERV's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
LOS ANGELES, April 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Investors eyeing a purchase of Verve Therapeutics Inc (VERV) shares, but tentative about paying the going market price of 13.11/share, might benefit from considering selling puts among the...